Published in Br J Haematol on June 01, 2001
Clinical implications of FLT3 mutations in pediatric AML. Blood (2006) 2.72
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leuk Lymphoma (2008) 1.93
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med (2006) 1.88
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn (2003) 1.82
Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res (2009) 1.72
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood (2006) 1.52
Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. Mol Cell Biol (2008) 1.32
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program (2013) 1.31
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood (2013) 1.31
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol (2014) 1.28
Cancer driver mutations in protein kinase genes. Cancer Lett (2008) 1.24
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. Leuk Lymphoma (2013) 1.21
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med (2010) 1.19
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia (2012) 1.18
Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer (2010) 1.17
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res (2009) 1.16
Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS One (2009) 1.14
Mechanisms of resistance to FLT3 inhibitors. Drug Resist Updat (2009) 1.05
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist (2011) 1.05
Bench to bedside targeting of FLT3 in acute leukemia. Curr Drug Targets (2010) 1.03
Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res (2011) 0.97
Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood (2012) 0.94
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. Blood (2007) 0.92
The Biology and Targeting of FLT3 in Pediatric Leukemia. Front Oncol (2014) 0.83
FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION. Nagoya J Med Sci (2015) 0.83
Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples. BMC Med Genomics (2012) 0.83
Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells. PLoS One (2013) 0.81
STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells. JAKSTAT (2012) 0.81
Pediatric oncology. Curr Opin Chem Biol (2007) 0.80
Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia. J Korean Med Sci (2008) 0.80
FLT3 mutations in canine acute lymphocytic leukemia. BMC Cancer (2011) 0.80
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev (2012) 0.80
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov (2016) 0.79
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs (2011) 0.79
Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation. J Cancer Res Clin Oncol (2005) 0.79
FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance. Mediterr J Hematol Infect Dis (2014) 0.78
Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis. Int J Mol Sci (2008) 0.77
Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones. J Hematol Oncol (2016) 0.77
Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients. Adv Hematol (2014) 0.76
Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants. Iran J Basic Med Sci (2014) 0.76
Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Rev Hematol (2014) 0.76
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. Oncotarget (2017) 0.76
FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia. Hematol Rep (2012) 0.75
Lack of FLT3-TKD835 gene mutation in toxicity of sulfur mustard in Iranian veterans. Iran J Basic Med Sci (2015) 0.75
The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. Indian J Hematol Blood Transfus (2015) 0.75
How I treat FLT3-mutated AML. Blood (2016) 0.75
Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features. Dis Markers (2013) 0.75
The Frequency of Mutations in Exon 11 of the c-kit Gene in Patients With Leukemia. Turk J Haematol (2012) 0.75
Recent advances and novel agents for FLT3 mutated acute myeloid leukemia. Stem Cell Investig (2014) 0.75
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer Res (2016) 0.75
Screening of C-kit gene Mutation in Acute Myeloid Leukaemia in Northern India. Iran J Cancer Prev (2012) 0.75
Analysis of Chromosomal Aberrations and FLT3 gene Mutations in Childhood Acute Myelogenous Leukemia Patients. Turk J Haematol (2012) 0.75
Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases. Elife (2017) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. Stem Cell Investig (2017) 0.75
Epigenetic Identity in AML Depends on Disruption of Non-promoter Regulatory Elements and is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer Discov (2017) 0.75
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs (2017) 0.75
Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. ACS Omega (2017) 0.75
Emerging therapies for acute myeloid leukemia: translating biology into the clinic. JCI Insight (2017) 0.75
The Regenstrief Medical Record System: 20 years of experience in hospitals, clinics, and neighborhood health centers. MD Comput (1992) 7.56
Isolation of a sequence-specific endonuclease (BamI) from Bacillus amyloliquefaciens H. J Mol Biol (1975) 7.42
Development of competence in the Bacillus subtilis transformation system. J Bacteriol (1967) 4.71
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Mechanism of integrating foreign DNA during transformation of Bacillus subtilis. Proc Natl Acad Sci U S A (1978) 3.74
Nutritional factors influencing the development of competence in the Bacillus subtilis transformation system. J Bacteriol (1968) 3.63
Factor VIII gene rearrangements in patients with severe haemophilia A. Lancet (1994) 3.56
Transformation and transfection in lysogenic strains of Bacillus subtilis 168. J Bacteriol (1973) 3.16
The effect of immediate access to a computerized medical record on physician test ordering: a controlled clinical trial in the emergency room. Am J Public Health (1982) 2.95
Transformation and transfection in lysogenic strains of Bacillus subtilis: evidence for selective induction of prophage in competent cells. J Bacteriol (1975) 2.80
Physician response to computer reminders. JAMA (1980) 2.73
Typing and subtyping of influenza viruses in clinical samples by PCR. J Clin Microbiol (1995) 2.72
Recognition sequence of specific endonuclease BamH.I from Bacillus amyloliquefaciens H. Nature (1977) 2.59
Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost (1998) 2.20
Intergenotic transformation of the Bacillus subtilis genospecies. J Bacteriol (1972) 2.07
Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol (2005) 1.96
Absolute CD4+ T-lymphocyte and CD34+ stem cell counts by single-platform flow cytometry: the way forward. Br J Haematol (1999) 1.90
Biochemical and genetic properties of site-specific restriction endonucleases in Bacillus globigii. J Bacteriol (1978) 1.81
Carrier detection by direct gene analysis in a family with haemophilia B (factor IX deficiency). Lancet (1984) 1.74
Metabolic and nutritional factors influencing the development of competence for transfection of Bacillus subtilis. Bacteriol Rev (1968) 1.73
FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol (2000) 1.50
Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. Clin Lab Haematol (2002) 1.46
Fibronectin in blood products--an in vitro and in vivo study. J Clin Pathol (1983) 1.42
Is routine molecular screening for common alpha-thalassaemia deletions necessary as part of an antenatal screening programme? J Med Screen (2007) 1.41
Inherited variants of factor-VIII-related protein in von Willebrand's disease. N Engl J Med (1974) 1.36
Characterization of temperate bacteriophages of Bacillus subtilis by the restriction endonuclease EcoRI: evidence for three different temperate bacteriophages. J Virol (1974) 1.32
High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol (1994) 1.29
Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene. Nucleic Acids Res (1991) 1.26
Proteolytic processing of reovirus is required for adherence to intestinal M cells. J Virol (1994) 1.26
Genetic testing for von Willebrand disease: the case for. J Thromb Haemost (2009) 1.24
Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. Br J Haematol (2000) 1.22
Facile and rapid analysis of three DNA polymorphisms within the human factor IX gene using the polymerase chain reaction. Br J Haematol (1991) 1.13
Heterogeneity of the factor IX locus in nine hemophilia B inhibitor patients. J Clin Invest (1987) 1.12
Expression of thymidylate synthetase activity in Bacillus subtilis upon integration of a cloned gene from Escherichia coli. Gene (1980) 1.10
The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia (2004) 1.10
Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Prepared by the CD34+ haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol (1999) 1.07
Evaluation of a novel stable whole blood quality control material for lymphocyte subset analysis: results from the UK NEQAS immune monitoring scheme. Cytometry (1996) 1.06
Affordable CD4+ T cell counts by flow cytometry. II. The use of fixed whole blood in resource-poor settings. J Immunol Methods (2001) 1.05
Contemporary gene flow and the spatio-temporal genetic structure of subdivided newt populations (Triturus cristatus, T. marmoratus). J Evol Biol (2005) 1.05
Effects of lysozyme on competence for Bacillus subtilis transfection. Biochim Biophys Acta (1970) 1.04
Effect of site-specific endonuclease digestion on the thyP3 gene of bacteriophage phi 3T and the thyP11 gene of bacteriophage rho11. Gene (1977) 1.04
Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood (1998) 1.04
A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood (2000) 1.02
Effect of lysogeny on transfection and transfection enhancement in Bacillus subtilis. J Bacteriol (1975) 1.01
Comparison of Tc99m polyphosphate and F18 for bone imaging. Am J Roentgenol Radium Ther Nucl Med (1974) 1.00
Transformation of Bacillus subtilis and Escherichia coli by a hybrid plasmid pCD1. Gene (1977) 1.00
Genomic structure of human FLT3: implications for mutational analysis. Br J Haematol (2001) 0.99
HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost (1997) 0.99
The use of the single radial haemolysis test for assessing antibody response and protective antibody levels in an influenza B vaccine study. J Biol Stand (1983) 0.98
Purification and properties of the BamHI endonuclease. Methods Enzymol (1980) 0.98
Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol (2005) 0.98
Lead poisoning due to Asian ethnic treatment for impotence. J R Soc Med (1991) 0.97
Precise carrier diagnosis in families with haemophilia A: use of conformation sensitive gel electrophoresis for mutation screening and polymorphism analysis. Thromb Haemost (1998) 0.97
Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol (2001) 0.97
Carrier detection in 50 haemophilia A kindred by means of three intragenic and two extragenic restriction fragment length polymorphisms. Br J Haematol (1988) 0.97
Linked and intragenic probes for haemophilia A. Lancet (1985) 0.96
Immunoradiometric assay of procoagulant factor-VIII antigen in plasma and serum and its reduction in haemophilia. Preliminary studies on adult and fetal blood. Lancet (1978) 0.96
Melatonin for treatment of sleep disorders in children with developmental disabilities. J Child Neurol (2001) 0.95
A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor. Thromb Haemost (2001) 0.95
Studies on the relationship between factor VIII related antigen (VIIIRAg) and factor VIII clotting antigen (VIIICAg) by immunoelectrophoresis and autoradiography using 125I anti VIIICAg. Thromb Res (1981) 0.95
Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost (1997) 0.94
The use of an immunoradiometric assay for factor VIII related antigen in the study of atypical Von Willebrand's disease. Thromb Res (1977) 0.94
Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood (2000) 0.94
Rapid two-stage PCR for detecting factor V G1691A mutation. Lancet (1994) 0.94
Extrapulmonary lymphomatoid granulomatosis presenting as Pancoast's syndrome. Postgrad Med J (1991) 0.94
Quality assessment of CD34+ stem cell enumeration: experience of the United Kingdom National External Quality Assessment Scheme (UK NEQAS) using a unique stable whole blood preparation. Br J Haematol (1998) 0.93
Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia (2004) 0.93
Are aberrant BCR--ABL transcripts more common than previously thought? Br J Haematol (2000) 0.92
The effect of aldosterone on colonic potential difference and renal electrolyte excretion in normal man. Clin Sci Mol Med (1974) 0.92
Distribution of fibronectin and laminin in normal and pathological lymphoid tissue. J Clin Pathol (1985) 0.91
Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood (2000) 0.91
Scrotal ulceration during all-trans retinoic (ATRA) therapy for acute promyelocytic leukaemia. Clin Lab Haematol (2000) 0.91
A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis. Br J Haematol (1999) 0.90
Factor VIII levels and blood group antigens. Thromb Haemost (1983) 0.90
Endothelial cell proliferation in myelofibrosis. Br J Haematol (1985) 0.89
Assembly of multimeric von Willebrand factor directs sorting of P-selectin. Arterioscler Thromb Vasc Biol (2000) 0.89
Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patients. J Antimicrob Chemother (1983) 0.89
Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw. Br J Haematol (1989) 0.89
Evaluation of leukocyte stabilisation in TransFix-treated blood samples by flow cytometry and transmission electron microscopy. J Immunol Methods (2004) 0.88
Tissue localization and synthesis of factor-VIII-related antigen in the human foetus. Br J Haematol (1974) 0.88
Gene structure, expression profiling and mutation analysis of the tumour suppressor SHIP1 in Caucasian acute myeloid leukaemia. Leukemia (2007) 0.88